News

AFT Pharmaceuticals announces opening of Share Purchase Plan

AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) is pleased to announce the opening of its NZ$2 million non-underwritten share purchase plan (SPP). The SPP is part of AFT Pharmaceuticals’ capital raising announced on 10 June 2020, whereby AFT also undertook a fully underwritten NZ$10 million placement of new shares to select investors in both local and offshore markets and certain major shareholders sold down NZ$63.8 million of existing shares (together, the Placement). AFT announced the successful completion of the Placement on 11 June 2020, which was strongly supported and fully subscribed at a price of NZ$3.75 per share.

Read More

AFT Pharmaceuticals announces successful completion of Placement

AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) is pleased to announce the successful completion of its NZ$73.8 million Placement (Placement), comprising a NZ$10 million primary issuance and a sell down by certain major shareholders of NZ$63.8 million of existing shares.

Read More

AFT Pharmaceuticals announces capital raising to support liquidity and optimise capital structure

AFT Pharmaceuticals (NZX:AFT, ASX:AFP) (AFT, the Company), Atkinson Family Trust (AF Trust) and CRG today announce a capital raising to increase liquidity and reduce debt.

Read More

Annual Meeting and Closing Date for Director Nominations

AFT Pharmaceuticals Limited (NZX: AFT, ASX: AFP) (AFT) announces that its Annual Meeting of Shareholders is to be held at 10:30am (NZT) on Wednesday 12 August 2020 in Milford, Auckland. Full details relating to the meeting, including webcast, will be advised in the Notice of Meeting, which will be distributed in due course.

Read More

Dispute with PBL Solutions Limited

AFT Pharmaceuticals Limited [NZX: AFT; ASX: AFP] advises that British Virgin Islands incorporated PBL Solutions Limited, the 35% shareholder in AFT’s 65% owned subsidiary AFT Orphan Pharmaceuticals Limited, has filed legal proceedings in the New Zealand High Court against AFT and Dr Hartley Atkinson. AFT disclosed this as a potential claim in its FY2020 results announcement dated 20 May 2020 and also in the notes to its FY2020 financial statements.

Read More

AFT secures Maxigesic IV® distribution in four Western European countries and reports Australasian market share gains in COVID-19 medicines

AFT Pharmaceuticals (NZX.AFT; ASX.AFP) today announces it has signed an exclusive distribution agreement with Austria’s Ever Valinject (Ever) for the commercialisation of Maxigesic IV®, the intravenous form of its patented analgesic, in a significant portion of Western Europe: Germany, Austria, Italy and France.

Read More

AFT Pharmaceuticals breaks through $100 million revenue and posts record earnings

Highlights

Read More

AFT Pharmaceuticals to announce full year results on Wednesday May 20 2020

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Wednesday May 20 2020 its full year results for the year ended March 31 2020. The release will be issued at around 09:00.

Read More

AFT finalises refinancing and gives trading update

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces it has concluded an agreement with the Bank of New Zealand (BNZ) to refinance its current six-year CRG loan facility maturing on 31 March 2020. This follows the term sheet concluded with the BNZ which was noted by AFT’s market announcement on 26 February 2020.

Read More

AFT on track to refinance CRG team loan facility

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces that its six-year term loan facility from CRG maturing on 31 March 2020 is on track to be refinanced with a three- year term loan from a local commercial bank.

Read More

AFT licenses Maxigesic® IV in 21 new countries across CIS and Central America

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces it has licensed its Maxigesic® intravenous medicine (Maxigesic® IV) in 21 new countries across the Commonwealth of Independent States (CIS) and Central America, territories with a combined population of more than 220 million people.

Read More

AFT notes Maxigesic® sales estimates in new market research

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) notes the publication of new market research that estimates the potential for AFT’s patented medicine Maxigesic in managing postoperative pain in the US, Japan and the top 5 European Union countries [France, Germany, Italy, Spain and UK].

Read More